TY  - JOUR
AU  - Rajkov, Branislava
AU  - Zdravković, Marija
AU  - Ninić, Ana
AU  - Brajković, Milica
AU  - Klašnja, Slobodan
AU  - Gardijan, Vera
AU  - Memon, Lidija
AU  - Munjas, Jelena
AU  - Mihajlović, Marija
AU  - Spasojević-Kalimanovska, Vesna
AU  - Radosavljević, Vojislav
AU  - Sopić, Miron
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4551
AB  - Purpose: Obstructive sleep apnea (OSA) is characterised by increased systemic inflammation, and is often accompanied with type 2 diabetes mellitus (T2DM) and cardiovascular disease. The aim of this investigation was to evaluate gene expression of resistin, its receptor CAP1 and CD36 as the indicators of the inflammatory changes in PBMCs in relation to the severity of OSA, and the presence of type 2 diabetes mellitus (T2DM) in OSA. Methods: Severity of OSA was defined by the apnea/hypopnea index (AHI): AHI < 30: mild to moderate OSA (MM-OSA), AHI ≥ 30: severe OSA (S-OSA). Presence of T2DM was captured: OSA with T2DM (OSA + T2DM), OSA without T2DM (OSA-T2DM). PBMC resistin, CAP1, and CD36 mRNA were determined by real-time PCR. Results: Resistin mRNA was significantly upregulated in S-OSA (N = 54) compared to the MM-OSA (N = 52, P = 0.043); CAP1 and CD36 mRNA levels did not differ between the groups (P = 0.302; P = 0.166, respectively). Resistin mRNA was significantly upregulated in OSA + T2DM (N = 29) compared to the OSA-T2DM (N = 77, P = 0.029); CAP1 and CD36 mRNA levels did not differ between the groups (P = 0.662; P = 0.108, respectively). AHI and T2DM were independent predictors of resistin mRNA above the 75th percentile (OR = 3.717 [1.152–11.991]; OR = 3.261 [1.000–10.630], P = 0.042 respectively). Conclusion: Resistin gene upregulation in S-OSA indicates its possible contribution to increased inflammation in S-OSA and makes it a possible marker of the disease severity. Resistin gene upregulation in OSA + T2DM suggests that a joint effect of these two comorbidities may have a major contribution to increased inflammation and complications that arise from this state.
PB  - Springer Nature
T2  - Sleep and Breathing
T1  - Upregulation of peripheral blood mononuclear cells resistin gene expression in severe obstructive sleep apnea and obstructive sleep apnea with coexisting type 2 diabetes mellitus
DO  - 10.1007/s11325-023-02809-0
ER  - 

@article{
author = "Rajkov, Branislava and Zdravković, Marija and Ninić, Ana and Brajković, Milica and Klašnja, Slobodan and Gardijan, Vera and Memon, Lidija and Munjas, Jelena and Mihajlović, Marija and Spasojević-Kalimanovska, Vesna and Radosavljević, Vojislav and Sopić, Miron",
year = "2023",
abstract = "Purpose: Obstructive sleep apnea (OSA) is characterised by increased systemic inflammation, and is often accompanied with type 2 diabetes mellitus (T2DM) and cardiovascular disease. The aim of this investigation was to evaluate gene expression of resistin, its receptor CAP1 and CD36 as the indicators of the inflammatory changes in PBMCs in relation to the severity of OSA, and the presence of type 2 diabetes mellitus (T2DM) in OSA. Methods: Severity of OSA was defined by the apnea/hypopnea index (AHI): AHI < 30: mild to moderate OSA (MM-OSA), AHI ≥ 30: severe OSA (S-OSA). Presence of T2DM was captured: OSA with T2DM (OSA + T2DM), OSA without T2DM (OSA-T2DM). PBMC resistin, CAP1, and CD36 mRNA were determined by real-time PCR. Results: Resistin mRNA was significantly upregulated in S-OSA (N = 54) compared to the MM-OSA (N = 52, P = 0.043); CAP1 and CD36 mRNA levels did not differ between the groups (P = 0.302; P = 0.166, respectively). Resistin mRNA was significantly upregulated in OSA + T2DM (N = 29) compared to the OSA-T2DM (N = 77, P = 0.029); CAP1 and CD36 mRNA levels did not differ between the groups (P = 0.662; P = 0.108, respectively). AHI and T2DM were independent predictors of resistin mRNA above the 75th percentile (OR = 3.717 [1.152–11.991]; OR = 3.261 [1.000–10.630], P = 0.042 respectively). Conclusion: Resistin gene upregulation in S-OSA indicates its possible contribution to increased inflammation in S-OSA and makes it a possible marker of the disease severity. Resistin gene upregulation in OSA + T2DM suggests that a joint effect of these two comorbidities may have a major contribution to increased inflammation and complications that arise from this state.",
publisher = "Springer Nature",
journal = "Sleep and Breathing",
title = "Upregulation of peripheral blood mononuclear cells resistin gene expression in severe obstructive sleep apnea and obstructive sleep apnea with coexisting type 2 diabetes mellitus",
doi = "10.1007/s11325-023-02809-0"
}

Rajkov, B., Zdravković, M., Ninić, A., Brajković, M., Klašnja, S., Gardijan, V., Memon, L., Munjas, J., Mihajlović, M., Spasojević-Kalimanovska, V., Radosavljević, V.,& Sopić, M.. (2023). Upregulation of peripheral blood mononuclear cells resistin gene expression in severe obstructive sleep apnea and obstructive sleep apnea with coexisting type 2 diabetes mellitus. in Sleep and Breathing
Springer Nature..
https://doi.org/10.1007/s11325-023-02809-0

Rajkov B, Zdravković M, Ninić A, Brajković M, Klašnja S, Gardijan V, Memon L, Munjas J, Mihajlović M, Spasojević-Kalimanovska V, Radosavljević V, Sopić M. Upregulation of peripheral blood mononuclear cells resistin gene expression in severe obstructive sleep apnea and obstructive sleep apnea with coexisting type 2 diabetes mellitus. in Sleep and Breathing. 2023;.
doi:10.1007/s11325-023-02809-0 .

Rajkov, Branislava, Zdravković, Marija, Ninić, Ana, Brajković, Milica, Klašnja, Slobodan, Gardijan, Vera, Memon, Lidija, Munjas, Jelena, Mihajlović, Marija, Spasojević-Kalimanovska, Vesna, Radosavljević, Vojislav, Sopić, Miron, "Upregulation of peripheral blood mononuclear cells resistin gene expression in severe obstructive sleep apnea and obstructive sleep apnea with coexisting type 2 diabetes mellitus" in Sleep and Breathing (2023),
https://doi.org/10.1007/s11325-023-02809-0 . .

TY  - JOUR
AU  - Milojević, Ana
AU  - Zdravković, Marija
AU  - Brajković, Milica
AU  - Memon, Lidija
AU  - Gardijan, Vera
AU  - Vekić, Jelena
AU  - Zeljković, Aleksandra
AU  - Stefanović, Aleksandra
AU  - Mihajlović, Marija
AU  - Ivanišević, Jasmina
AU  - Bogavac-Stanojević, Nataša
AU  - Radosavljević, Vojislav
AU  - Spasojević-Kalimanovska, Vesna
AU  - Ninić, Ana
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4199
AB  - Objectives: Obstructive sleep apnea (OSA) is a common condition closely related to obesity, insulin resistance, dyslipidemia, and cardiovascular disease. The aim of this study was to explore the possible relationship between OSA and proprotein convertase subtilisin/kexin type 9 (PCSK9). Methods: Full-night polysomnography was performed on 150 participants who were divided into three groups: controls, OSA patients on statin therapy, and OSA patients not on statin therapy. Biochemical markers, plasma low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subclasses, and PCSK9 were determined. Results: PCSK9 was highest in OSA patients on statins compared to the control group and to OSA patients not on statins (p = 0.036 and p = 0.039, respectively), after adjustment for body mass index (BMI). LDL diameter was greater in OSA patients not on statins compared to OSA patients on statins (p = 0.032). PCSK9 was highest in the group of patients with all three risk factors (diagnosed OSA, statins, BMI ≥25 kg/m2) compared to groups with no, one, and two risk factors (p = 0.031, p = 0.001, and p = 0.029, respectively). Presence of OSA, statin therapy, and BMI ≥25 kg/m2 when combined were independently associated with higher levels of PCSK9 when adjusted for antihypertensive therapy, small dense LDL, and HDL 3c subclass (odds ratio = 2.849; interquartile range [1.026–7.912], p = 0.044). Conclusion: Statin therapy was closely related to PCSK9. OSA along with obesity and statin use induces elevation of PCSK9.
PB  - S. Karger AG Basel
T2  - Medical Principles and Practice
T1  - Effects of Apnea, Obesity, and Statin Therapy on
Proprotein Convertase Subtilisin/Kexin 9 Levels
in Patients with Obstructive Sleep Apnea
VL  - 31
IS  - 3
SP  - 293
EP  - 300
DO  - 10.1159/000524087
ER  - 

@article{
author = "Milojević, Ana and Zdravković, Marija and Brajković, Milica and Memon, Lidija and Gardijan, Vera and Vekić, Jelena and Zeljković, Aleksandra and Stefanović, Aleksandra and Mihajlović, Marija and Ivanišević, Jasmina and Bogavac-Stanojević, Nataša and Radosavljević, Vojislav and Spasojević-Kalimanovska, Vesna and Ninić, Ana",
year = "2022",
abstract = "Objectives: Obstructive sleep apnea (OSA) is a common condition closely related to obesity, insulin resistance, dyslipidemia, and cardiovascular disease. The aim of this study was to explore the possible relationship between OSA and proprotein convertase subtilisin/kexin type 9 (PCSK9). Methods: Full-night polysomnography was performed on 150 participants who were divided into three groups: controls, OSA patients on statin therapy, and OSA patients not on statin therapy. Biochemical markers, plasma low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subclasses, and PCSK9 were determined. Results: PCSK9 was highest in OSA patients on statins compared to the control group and to OSA patients not on statins (p = 0.036 and p = 0.039, respectively), after adjustment for body mass index (BMI). LDL diameter was greater in OSA patients not on statins compared to OSA patients on statins (p = 0.032). PCSK9 was highest in the group of patients with all three risk factors (diagnosed OSA, statins, BMI ≥25 kg/m2) compared to groups with no, one, and two risk factors (p = 0.031, p = 0.001, and p = 0.029, respectively). Presence of OSA, statin therapy, and BMI ≥25 kg/m2 when combined were independently associated with higher levels of PCSK9 when adjusted for antihypertensive therapy, small dense LDL, and HDL 3c subclass (odds ratio = 2.849; interquartile range [1.026–7.912], p = 0.044). Conclusion: Statin therapy was closely related to PCSK9. OSA along with obesity and statin use induces elevation of PCSK9.",
publisher = "S. Karger AG Basel",
journal = "Medical Principles and Practice",
title = "Effects of Apnea, Obesity, and Statin Therapy on
Proprotein Convertase Subtilisin/Kexin 9 Levels
in Patients with Obstructive Sleep Apnea",
volume = "31",
number = "3",
pages = "293-300",
doi = "10.1159/000524087"
}

Milojević, A., Zdravković, M., Brajković, M., Memon, L., Gardijan, V., Vekić, J., Zeljković, A., Stefanović, A., Mihajlović, M., Ivanišević, J., Bogavac-Stanojević, N., Radosavljević, V., Spasojević-Kalimanovska, V.,& Ninić, A.. (2022). Effects of Apnea, Obesity, and Statin Therapy on
Proprotein Convertase Subtilisin/Kexin 9 Levels
in Patients with Obstructive Sleep Apnea. in Medical Principles and Practice
S. Karger AG Basel., 31(3), 293-300.
https://doi.org/10.1159/000524087

Milojević A, Zdravković M, Brajković M, Memon L, Gardijan V, Vekić J, Zeljković A, Stefanović A, Mihajlović M, Ivanišević J, Bogavac-Stanojević N, Radosavljević V, Spasojević-Kalimanovska V, Ninić A. Effects of Apnea, Obesity, and Statin Therapy on
Proprotein Convertase Subtilisin/Kexin 9 Levels
in Patients with Obstructive Sleep Apnea. in Medical Principles and Practice. 2022;31(3):293-300.
doi:10.1159/000524087 .

Milojević, Ana, Zdravković, Marija, Brajković, Milica, Memon, Lidija, Gardijan, Vera, Vekić, Jelena, Zeljković, Aleksandra, Stefanović, Aleksandra, Mihajlović, Marija, Ivanišević, Jasmina, Bogavac-Stanojević, Nataša, Radosavljević, Vojislav, Spasojević-Kalimanovska, Vesna, Ninić, Ana, "Effects of Apnea, Obesity, and Statin Therapy on
Proprotein Convertase Subtilisin/Kexin 9 Levels
in Patients with Obstructive Sleep Apnea" in Medical Principles and Practice, 31, no. 3 (2022):293-300,
https://doi.org/10.1159/000524087 . .

TY  - JOUR
AU  - Ninić, Ana
AU  - Zdravković, Marija
AU  - Radosavljević, Vojislav
AU  - Gardijan, Vera
AU  - Memon, Lidija
AU  - Vekić, Jelena
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3769
AB  - Obstructive  sleep  apnea  (OSA)  as  a  worldwide  prevalent  condition  carries  risk  for cardiovascular  and  metabolic  diseases,  ultimately  increasingoverall  mortality  rates.  Non-alcoholic fatty liver disease  (NAFLD) can be considered as the primary metabolic  disease,  but also as a coexisting OSA comorbidity. Although prevalence of NAFLD covers quarter of world population, it increases with OSA presence. It can be speculated that chronic intermittent hypoxia (CIH)  and  sympathetic  nervous  system  overactivity  are  involved  in  NAFLD  pathogenesis  and progression   from   simple   steatosis throughsteatohepatitis   to   fibrosis.   CIH   provides   the environment  for  liveroxidative  stress,  inflammation  and  increases  the  expression  of  genes involved in cholesterol and fatty acids synthesis. Catecholamines increase β-oxidation in liver and release free fatty acids from adipose tissue in plasma which inhibit insulin effects. Obesity and insulin resistance as key playersin NAFLD development and advancement, deepen vicious circle of oxidative stress, inflammation and dyslipidemia. If not treated, OSA in NAFLD patients has been  associated  with inflammation, hepatocytes’ necrosis,  and  fibrosis.  Continuous  positive airway pressure (CPAP) represents gold standard for OSA therapy, allowing the unimpeded air passage through upper parts of respiratory system. However, it has been demonstrated that CPAP therapyhave beneficial effects on cardiometabolic outcomes and slowliver degeneration
AB  - Opstruktivna apneja u snu (OSA) kao oboljenje prevalentno u svetu nosi rizik za nastanak kardiovaskularnih i metaboličkih bolesti, povećavajući ukupnu smrtnost. Bolest nealkoholne masne jetre (eng. non-alcoholic fatty liver disease -NAFLD) se može smatrati primarnom metaboličkom bolešću, ali kao i komorbiditet OSA. Iako prevalenca NAFLD obuhvata četvrtinu svetske populacije, ona se povećava sa prisustvom OSA. Pretpostavlja se da su hronična intermitentna hipoksija (eng. chronic intermittent hypoxia -CIH) i prekomerna aktivnost simpatičkog nervnog sistema uključeni u patogenezu NAFLD i progresiju od steatoze preko steatohepatitisa do fibroze. U jetri CIH stvara uslove za oksidativni stres, inflamaciju i povećava ekspresiju gena koji učestvuju u sintezi holesterola i masnih kiselina. Kateholamini stimulišu b-oksidaciju masnih kiselina u jetri i oslobađaju slobodne masne kiseline iz masnog tkiva u plazmu, koje inhibiraju dejstva insulina. Gojaznost i insulinska rezistencija kao ključni faktori u razvoju i napredovanju NAFLD produbljuju začarani krug oksidativnog stresa, inflamacije i dislipidemije. Ako se ne leči, OSA kod pacijenata sa NAFLD je povezana sa inflamacijom, nekrozom hepatocita i fibrozom. Kontinuirani pozitivni pritisak vazduha (eng. continuous positive airway pressure -CPAP) predstavlja zlatni standard u terapiji OSA, koji omogućava neometani prolaz vazduha kroz gornje delove respiratornog sistema. Međutim, CPAP terapija je pokazala da ima povoljne efekte na kardiometaboličke ishode i da usporava degeneraciju jetre.
PB  - Pharmaceutical Association of Serbia
T2  - Arhiv za farmaciju
T1  - Non-alcoholic fatty liver disease as metabolic consequence of obstructive sleep apnea
T1  - Bolest nealkoholne masne jetre kao metabolička posledica opstruktivne apneje u snu
VL  - 70
IS  - 6
SP  - 319
EP  - 331
DO  - 10.5937/arhfarm70-27586
ER  - 

@article{
author = "Ninić, Ana and Zdravković, Marija and Radosavljević, Vojislav and Gardijan, Vera and Memon, Lidija and Vekić, Jelena and Spasojević-Kalimanovska, Vesna",
year = "2020",
abstract = "Obstructive  sleep  apnea  (OSA)  as  a  worldwide  prevalent  condition  carries  risk  for cardiovascular  and  metabolic  diseases,  ultimately  increasingoverall  mortality  rates.  Non-alcoholic fatty liver disease  (NAFLD) can be considered as the primary metabolic  disease,  but also as a coexisting OSA comorbidity. Although prevalence of NAFLD covers quarter of world population, it increases with OSA presence. It can be speculated that chronic intermittent hypoxia (CIH)  and  sympathetic  nervous  system  overactivity  are  involved  in  NAFLD  pathogenesis  and progression   from   simple   steatosis throughsteatohepatitis   to   fibrosis.   CIH   provides   the environment  for  liveroxidative  stress,  inflammation  and  increases  the  expression  of  genes involved in cholesterol and fatty acids synthesis. Catecholamines increase β-oxidation in liver and release free fatty acids from adipose tissue in plasma which inhibit insulin effects. Obesity and insulin resistance as key playersin NAFLD development and advancement, deepen vicious circle of oxidative stress, inflammation and dyslipidemia. If not treated, OSA in NAFLD patients has been  associated  with inflammation, hepatocytes’ necrosis,  and  fibrosis.  Continuous  positive airway pressure (CPAP) represents gold standard for OSA therapy, allowing the unimpeded air passage through upper parts of respiratory system. However, it has been demonstrated that CPAP therapyhave beneficial effects on cardiometabolic outcomes and slowliver degeneration, Opstruktivna apneja u snu (OSA) kao oboljenje prevalentno u svetu nosi rizik za nastanak kardiovaskularnih i metaboličkih bolesti, povećavajući ukupnu smrtnost. Bolest nealkoholne masne jetre (eng. non-alcoholic fatty liver disease -NAFLD) se može smatrati primarnom metaboličkom bolešću, ali kao i komorbiditet OSA. Iako prevalenca NAFLD obuhvata četvrtinu svetske populacije, ona se povećava sa prisustvom OSA. Pretpostavlja se da su hronična intermitentna hipoksija (eng. chronic intermittent hypoxia -CIH) i prekomerna aktivnost simpatičkog nervnog sistema uključeni u patogenezu NAFLD i progresiju od steatoze preko steatohepatitisa do fibroze. U jetri CIH stvara uslove za oksidativni stres, inflamaciju i povećava ekspresiju gena koji učestvuju u sintezi holesterola i masnih kiselina. Kateholamini stimulišu b-oksidaciju masnih kiselina u jetri i oslobađaju slobodne masne kiseline iz masnog tkiva u plazmu, koje inhibiraju dejstva insulina. Gojaznost i insulinska rezistencija kao ključni faktori u razvoju i napredovanju NAFLD produbljuju začarani krug oksidativnog stresa, inflamacije i dislipidemije. Ako se ne leči, OSA kod pacijenata sa NAFLD je povezana sa inflamacijom, nekrozom hepatocita i fibrozom. Kontinuirani pozitivni pritisak vazduha (eng. continuous positive airway pressure -CPAP) predstavlja zlatni standard u terapiji OSA, koji omogućava neometani prolaz vazduha kroz gornje delove respiratornog sistema. Međutim, CPAP terapija je pokazala da ima povoljne efekte na kardiometaboličke ishode i da usporava degeneraciju jetre.",
publisher = "Pharmaceutical Association of Serbia",
journal = "Arhiv za farmaciju",
title = "Non-alcoholic fatty liver disease as metabolic consequence of obstructive sleep apnea, Bolest nealkoholne masne jetre kao metabolička posledica opstruktivne apneje u snu",
volume = "70",
number = "6",
pages = "319-331",
doi = "10.5937/arhfarm70-27586"
}

Ninić, A., Zdravković, M., Radosavljević, V., Gardijan, V., Memon, L., Vekić, J.,& Spasojević-Kalimanovska, V.. (2020). Non-alcoholic fatty liver disease as metabolic consequence of obstructive sleep apnea. in Arhiv za farmaciju
Pharmaceutical Association of Serbia., 70(6), 319-331.
https://doi.org/10.5937/arhfarm70-27586

Ninić A, Zdravković M, Radosavljević V, Gardijan V, Memon L, Vekić J, Spasojević-Kalimanovska V. Non-alcoholic fatty liver disease as metabolic consequence of obstructive sleep apnea. in Arhiv za farmaciju. 2020;70(6):319-331.
doi:10.5937/arhfarm70-27586 .

Ninić, Ana, Zdravković, Marija, Radosavljević, Vojislav, Gardijan, Vera, Memon, Lidija, Vekić, Jelena, Spasojević-Kalimanovska, Vesna, "Non-alcoholic fatty liver disease as metabolic consequence of obstructive sleep apnea" in Arhiv za farmaciju, 70, no. 6 (2020):319-331,
https://doi.org/10.5937/arhfarm70-27586 . .